Lilly Retatrutide Tops Ozempic
I denne episoden
- Lilly Retatrutide Tops Ozempic
- Genmab Petosemtamab Hits Survival
- Radiotherapy Improves Lung Survival
- Merck Leak Leads ESMO
Kilder
- BioSpace: Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
- Finance: Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial - Yahoo Finance
- BioSpace: Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
- Pharmatimes: Radiotherapy boosts progression‑free survival in advanced lung cancer
- BioSpace: Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.